tiprankstipranks
Pacira (PCRX)
NASDAQ:PCRX
US Market
PCRX
Pacira Pharmaceuticals
RESEARCH TOOLSreports
Want to see PCRX full AI Analyst Report?

Pacira Pharmaceuticals (PCRX) Stock Forecast & Price Target

385 Followers
See the Price Targets and Ratings of:

PCRX Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
3 Buy
2 Hold
1 Sell
Based on 6 analysts giving stock ratings to
Pacira
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PCRX Stock 12 Month Forecast

Average Price Target

$28.40
▲(14.89% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Pacira Pharmaceuticals in the last 3 months. The average price target is $28.40 with a high forecast of $38.00 and a low forecast of $23.00. The average price target represents a 14.89% change from the last price of $24.72.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","39":"$39","24.75":"$24.8","29.5":"$29.5","34.25":"$34.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,24.75,29.5,34.25,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.44,25.483076923076926,26.526153846153846,27.56923076923077,28.612307692307695,29.655384615384616,30.69846153846154,31.74153846153846,32.784615384615385,33.82769230769231,34.87076923076923,35.91384615384615,36.956923076923076,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.44,24.744615384615386,25.04923076923077,25.353846153846156,25.658461538461538,25.963076923076922,26.267692307692307,26.572307692307692,26.876923076923077,27.181538461538462,27.486153846153847,27.79076923076923,28.095384615384614,{"y":28.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.44,24.32923076923077,24.21846153846154,24.107692307692307,23.99692307692308,23.886153846153846,23.775384615384617,23.664615384615384,23.553846153846155,23.443076923076923,23.332307692307694,23.22153846153846,23.11076923076923,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.24,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.25,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":22.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.22,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.38,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.88,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.22,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.28,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.79,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.44,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$38.00Average Price Target$28.40Lowest Price Target$23.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on PCRX
Jenna Davidner
Barclays
Barclays
$25
Hold
1.13%
Upside
Reiterated
05/14/26
Barclays Sticks to Its Hold Rating for Pacira Pharmaceuticals (PCRX)
H.C. Wainwright Analyst forecast on PCRX
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$38
Buy
53.72%
Upside
Reiterated
05/04/26
H.C. Wainwright Reaffirms Their Buy Rating on Pacira Pharmaceuticals (PCRX)
Needham Analyst forecast on PCRX
Serge Belanger
Needham
Needham
$30→$32
Buy
29.45%
Upside
Reiterated
05/01/26
Analysts Are Bullish on Top Healthcare Stocks: Irhythm Technologies (IRTC), Pacira Pharmaceuticals (PCRX)
Truist Financial Analyst forecast on PCRX
Les Sulewski
Truist Financial
Truist Financial
―
Buy
―
Reiterated
05/01/26
Analysts' Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)
RBC Capital Analyst forecast on PCRX
Douglas Miehm
RBC Capital
RBC Capital
$22→$24
Hold
-2.91%
Downside
Reiterated
04/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), Merit Medical Systems (NASDAQ: MMSI) and Ardelyx (NASDAQ: ARDX)
J.P. Morgan Analyst forecast on PCRX
Hardik Parikh
J.P. Morgan
J.P. Morgan
$23
Sell
-6.96%
Downside
Reiterated
03/20/26
J.P. Morgan Sticks to Their Sell Rating for Pacira Pharmaceuticals (PCRX)
Jefferies Analyst forecast on PCRX
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$36
Buy
45.63%
Upside
Reiterated
01/09/26
Jefferies Remains a Buy on Pacira Pharmaceuticals (PCRX)
Canaccord Genuity Analyst forecast on PCRX
Gary Nachman
Canaccord Genuity
Canaccord Genuity
―
Hold
―
Reiterated
10/06/25
Raymond James Sticks to Their Hold Rating for Pacira Pharmaceuticals (PCRX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on PCRX
Jenna Davidner
Barclays
Barclays
$25
Hold
1.13%
Upside
Reiterated
05/14/26
Barclays Sticks to Its Hold Rating for Pacira Pharmaceuticals (PCRX)
H.C. Wainwright Analyst forecast on PCRX
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$38
Buy
53.72%
Upside
Reiterated
05/04/26
H.C. Wainwright Reaffirms Their Buy Rating on Pacira Pharmaceuticals (PCRX)
Needham Analyst forecast on PCRX
Serge Belanger
Needham
Needham
$30→$32
Buy
29.45%
Upside
Reiterated
05/01/26
Analysts Are Bullish on Top Healthcare Stocks: Irhythm Technologies (IRTC), Pacira Pharmaceuticals (PCRX)
Truist Financial Analyst forecast on PCRX
Les Sulewski
Truist Financial
Truist Financial
―
Buy
―
Reiterated
05/01/26
Analysts' Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)
RBC Capital Analyst forecast on PCRX
Douglas Miehm
RBC Capital
RBC Capital
$22→$24
Hold
-2.91%
Downside
Reiterated
04/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), Merit Medical Systems (NASDAQ: MMSI) and Ardelyx (NASDAQ: ARDX)
J.P. Morgan Analyst forecast on PCRX
Hardik Parikh
J.P. Morgan
J.P. Morgan
$23
Sell
-6.96%
Downside
Reiterated
03/20/26
J.P. Morgan Sticks to Their Sell Rating for Pacira Pharmaceuticals (PCRX)
Jefferies Analyst forecast on PCRX
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$36
Buy
45.63%
Upside
Reiterated
01/09/26
Jefferies Remains a Buy on Pacira Pharmaceuticals (PCRX)
Canaccord Genuity Analyst forecast on PCRX
Gary Nachman
Canaccord Genuity
Canaccord Genuity
―
Hold
―
Reiterated
10/06/25
Raymond James Sticks to Their Hold Rating for Pacira Pharmaceuticals (PCRX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pacira Pharmaceuticals

3 Months
Hardik ParikhJ.P. Morgan
Success Rate
4/11 ratings generated profit
36%
Average Return
-9.03%
Copying Hardik Parikh's trades and holding each position for 3 Months would result in 36.36% of your transactions generating a profit, with an average return of -9.03% per trade.
1 Year
Hardik ParikhJ.P. Morgan
Success Rate
5/11 ratings generated profit
45%
Average Return
-17.73%
Copying Hardik Parikh's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -17.73% per trade.
2 Years
Hardik ParikhJ.P. Morgan
Success Rate
5/11 ratings generated profit
45%
Average Return
-15.45%
Copying Hardik Parikh's trades and holding each position for 2 Years would result in 45.45% of your transactions generating a profit, with an average return of -15.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PCRX Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
5
4
4
3
3
Buy
5
5
4
3
3
Hold
2
2
2
3
3
Sell
1
0
1
1
1
Strong Sell
0
0
0
0
0
total
13
11
11
10
10
In the current month, PCRX has received 6 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. PCRX average Analyst price target in the past 3 months is 28.40.
Each month's total comprises the sum of three months' worth of ratings.

PCRX Financial Forecast

PCRX Earnings Forecast

Next quarter’s earnings estimate for PCRX is $0.65 with a range of $0.52 to $0.76. The previous quarter’s EPS was $0.60. PCRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PCRX has Performed in-line its overall industry.
Next quarter’s earnings estimate for PCRX is $0.65 with a range of $0.52 to $0.76. The previous quarter’s EPS was $0.60. PCRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PCRX has Performed in-line its overall industry.

PCRX Sales Forecast

Next quarter’s sales forecast for PCRX is $190.54M with a range of $188.00M to $192.60M. The previous quarter’s sales results were $177.38M. PCRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PCRX has Performed in-line its overall industry.
Next quarter’s sales forecast for PCRX is $190.54M with a range of $188.00M to $192.60M. The previous quarter’s sales results were $177.38M. PCRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PCRX has Performed in-line its overall industry.

PCRX Stock Forecast FAQ

What is PCRX’s average 12-month price target, according to analysts?
Based on analyst ratings, Pacira’s 12-month average price target is 28.40.
    What is PCRX’s upside potential, based on the analysts’ average price target?
    Pacira has 14.89% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PCRX a Buy, Sell or Hold?
          Pacira has a consensus rating of Moderate Buy which is based on 3 buy ratings, 2 hold ratings and 1 sell ratings.
            What is Pacira’s price target?
            The average price target for Pacira is 28.40. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $38.00 ,the lowest forecast is $23.00. The average price target represents 14.89% Increase from the current price of $24.72.
              What do analysts say about Pacira?
              Pacira’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of PCRX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.